• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Proteomic profiling reveals a distinctive molecular signature for critically ill COVID-19 patients compared with asthma and COPD

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2022 Jan 8;S1201-9712(22)00001-7.
doi: 10.1016/j.ijid.2022.01.008. Online ahead of print.
Proteomic profiling reveals a distinctive molecular signature for critically ill COVID-19 patients compared with asthma and COPD: A distinctive molecular signature for critically ill COVID-19 patients


Zili Zhang[SUP] 1 [/SUP], Fanjie Lin[SUP] 1 [/SUP], Fei Liu[SUP] 2 [/SUP], Qiongqiong Li[SUP] 1 [/SUP], Yuanyuan Li[SUP] 1 [/SUP], Zhanbei Zhu[SUP] 1 [/SUP], Hua Guo[SUP] 1 [/SUP], Lidong Liu[SUP] 3 [/SUP], Xiaoqing Liu[SUP] 1 [/SUP], Wei Liu[SUP] 1 [/SUP], Yaowei Fang[SUP] 1 [/SUP], Xinguang Wei[SUP] 1 [/SUP], Wenju Lu[SUP] 4 [/SUP]



Affiliations

Abstract

Objective: The mortality rate for critically ill coronavirus disease 2019 (COVID-19) cases was more than 80%. Nonetheless, research about the effect of common respiratory diseases on critically ill COVID-19 expression and outcomes is scarce.
Design: We performed proteomic analyses on airway mucus obtained by bronchoscopy from severe COVID-19 patients, or induced sputum from patients with chronic obstructive pulmonary disease (COPD), asthma, and healthy controls.
Results: Out of the total identified and quantified proteins, 445 differentially expressed proteins (DEPs) were found in different comparison groups. In comparison to COPD, asthma, and controls, 11 proteins were uniquely present in COVID-19 patients. Apart from DEPs associated with COPD vs controls and asthma vs controls, there were a total of 59 DEPs specific to COVID-19 patients. Finally, the findings revealed that there were 8 overlapping proteins in COVID-19 patients, including C9, FGB, FGG, PRTN3, HBB, HBA1, IGLV3-19, and COTL1. Functional analyses revealed that the majority of them were associated with complement and coagulation cascades, platelet activation, or iron metabolism, and anemia-related pathways.
Conclusions: This study provides fundamental data for identifying COVID-19-specific proteomic changes in comparison to COPD and asthma, which may suggest molecular targets for specialized therapy.

Keywords: Airway mucus; Asthma; COPD; Critically ill COVID-19; Proteomic sequencing.
 
Back
Top Bottom